- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03021993
Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
Phase II Trial of Nivolumab, an Anti-PD-1 Monoclonal Antibody, as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
Visão geral do estudo
Descrição detalhada
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Medical University of South Carolina
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Newly diagnosed histologically proven locoregional OCSCC without evidence of distant metastases and a clinically determined T-stage of 2-4,
OR
Recurrent or persistent histologically proven locoregional OCSCC that was initially treated with surgery alone, and a clinically determined recurrent T-stage of 2-4.
Note - OCSCC includes the subsites of oral tongue, floor of mouth, gingiva, retromolar trigone, and buccal mucosa.
Note - To allow sufficient tumor tissue for the immunological analyses, patients with T-stage 1 OCSCC will be excluded
- Greater than or equal to 18 years of age
- ECOG performance status of 0 or 1
Screening labs must meet the following criteria and must be obtained within 14 days prior to registration:
- WBC > 2,000/µL
- Absolute Neutrophil Count >1,500/µL
- Platelets > 100 X 103/µL
- Hemoglobin > 9.0 g/dL
- Serum creatinine < 1.5 X ULN or CrCl > 40mL/min (if using the Cockcroft-Gault formula below):
Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL
- AST/ALT ≤ 3 x ULN
- Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
- Reproductive Status:
WOCBP must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug.
Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception with a failure rate of less than 1% per year for a period of 31 weeks after the last dose of investigational product.
WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 consecutive months of amenorrhea in a woman over 45.
Women of childbearing potential must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to registration Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and azoospermic men, are not required to use contraception.
Exclusion Criteria:
- Prior immunotherapy or treatment with another anti PD 1 agent
- Prior chemotherapy including Cetuximab or radiation therapy
- Previous severe hypersensitivity reaction to another monoclonal antibody
- Women who are pregnant, lactating or expecting to conceive
- Men who are expecting to father children within the research period
- Known history of HIV or AIDS
- Positive test for HBV sAg or HCV antibody indicating acute or chronic infection
- Concomitant malignancies except cutaneous squamous cell carcinoma or basal cell carcinoma
- Unresectable primary tumor or regional disease; presence of distant metastases.
- History of pneumonitis or interstitial lung disease
- Active, known or suspected autoimmune disease. Note: Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
- Presence of condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Nivolumab
Nivolumab (OPDIVO) will be administered every two weeks for up to four doses prior to surgery at 3mg/kg
|
Nivolumab will be administered on days 1, 15 and 29.
If disease has progressed at day 29, the subject will proceed to surgery.
If a response or stable disease is present after the third dose, a fourth dose will be given on day 43, then the subject will proceed to surgery.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Objective response rate using pathological response
Prazo: Time of surgery (day 36 or day 50)
|
Objective response rate: the sum of patients with either a pCR defined as no invasive and no in situ residuals present in the surgical specimen or partial pathologic response defined at least a 30% reduction in the size of the lesion in the surgical specimen.
The reduction in size will be determined by comparing the pretreatment clinical measurements (the sum of the greatest axial measurement obtained with calipers at the time of initial evaluation) with the final pathologic measurements.
|
Time of surgery (day 36 or day 50)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Level of Treg cells in peripheral blood using immunostaining
Prazo: Day 1 and time of surgery (day 36 or day 50)
|
1. Levels of Treg cells in pre and post treatment peripheral blood will be evaluated using immunostaining for CD4 and flow cytometric analysis of Foxp3.
Differences will be calculated (absolute change and percentage change) between pre and post treatment measures.
|
Day 1 and time of surgery (day 36 or day 50)
|
Level of activated T-cells in peripheral blood
Prazo: Day 1 and time of surgery (day 36 or day 50)
|
2. Levels of activated T-cells in peripheral blood will be assessed using flow cytometry for expression of CD69, IFN γ, T-bet and ICOS in CD4+ cells.
Differences will be calculated (absolute change and percentage change) between pre and post treatment measures.
|
Day 1 and time of surgery (day 36 or day 50)
|
Level of immune stimulatory cytokines in peripheral blood
Prazo: Day 1 and time of surgery (day 36 or day 50)
|
3. Intratumoral immune activity assessed by levels of immune stimulatory cytokines including IL-2, IFN γ, and IL-12 or inhibitory cytokine, IL10 and TGF-beta, in OCSCC tumor lysates will be measured flow cytometrically by cytokine bead array.
Differences will be calculated (absolute change and percentage change) between pre and post treatment measures.
|
Day 1 and time of surgery (day 36 or day 50)
|
Expression of Th1 responses in CD4+ cells from peripheral blood
Prazo: Day 1 and time of surgery (day 36 or day 50)
|
Expression of IL-2 (Th1 responses) in CD4+ cells from peripheral blood of patients following PD-1 inhibition therapy will be compared between pre-treatment peripheral blood samples and post-treatment samples from the same patient.
|
Day 1 and time of surgery (day 36 or day 50)
|
Expression of Th2 responses in CD4+ cells from peripheral blood
Prazo: Day 1 and time of surgery (day 36 or day 50)
|
Expression of IIL 10 (Th2 responses) in CD4+ cells from peripheral blood of patients following PD-1 inhibition therapy will be compared between pre-treatment peripheral blood samples and post-treatment samples from the same patient.
|
Day 1 and time of surgery (day 36 or day 50)
|
Expression of CD8+ cells expressing granzyme B (ctolytic response) from peripheral blood
Prazo: Day 1 and time of surgery (day 36 or day 50)
|
2. Expression of CD8+ cells expressing granzyme B (cytolytic response) from peripheral blood of patients following PD-1 inhibition therapy will be compared between pre-treatment peripheral blood samples and post-treatment samples from the same patient.
|
Day 1 and time of surgery (day 36 or day 50)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: David Neskey, MD, Medical University of South Carolina
Publicações e links úteis
Publicações Gerais
- Knochelmann HM, Horton JD, Liu S, Armeson K, Kaczmar JM, Wyatt MM, Richardson MS, Lomeli SH, Xiong Y, Graboyes EM, Lentsch EJ, Hornig JD, Skoner J, Stalcup S, Spampinato MV, Garrett-Mayer E, O'Quinn EC, Timmers CD, Romeo MJ, Wrangle JM, Young MRI, Rubinstein MP, Day TA, Lo RS, Paulos CM, Neskey DM. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 Oct 19;2(10):100426. doi: 10.1016/j.xcrm.2021.100426. eCollection 2021 Oct 19.
- Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, Lim RJ, Wang Y, Dumitras C, Krysan K, Timmers C, Romeo MJ, Krieg C, O'Quinn EC, Horton JD, Dubinett SM, Paulos CM, Neskey DM, Lo RS. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med. 2021 Oct 19;2(10):100411. doi: 10.1016/j.xcrm.2021.100411. eCollection 2021 Oct 19.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 102510
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Oral Cavity SCC
-
International Agency for Research on CancerUniversity of Cambridge; Kilimanjaro Clinical Research InstituteConcluídoDoenças Esofágicas | Esôfago SCCTanzânia
-
University of California, DavisConcluídoPreocupações Cognitivas Subjetivas (SCC)Estados Unidos
-
SirnaomicsConcluído
-
Novartis PharmaceuticalsRecrutamentoAdvanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal Squamous CellCancer (SCC),Head/Pneck SCC,MelanomaHolanda, Republica da Coréia, Espanha, Taiwan, Japão, Itália, Canadá, Estados Unidos, Cingapura
-
University of HohenheimConcluídoSegurança Após Ingestão Oral | Farmacocinética após ingestão oralAlemanha
-
University of HohenheimConcluídoSegurança Após Ingestão Oral | Farmacocinética após ingestão oralAlemanha
-
University of HohenheimGerman Federal Ministry of Economics and TechnologyConcluídoSegurança Após Ingestão Oral | Farmacocinética após ingestão oralAlemanha
-
Rigshospitalet, DenmarkConcluídoCâncer bucal | Língua SCCDinamarca
-
University of HohenheimUniversität TübingenConcluídoSegurança Após Ingestão Oral | Farmacocinética após ingestão oral | Atividade das Células ImunesAlemanha
Ensaios clínicos em Nivolumab
-
Clinica Universidad de Navarra, Universidad de...Highlight TherapeuticsRecrutamentoCâncer de Pulmão de Células Não Pequenas MetastáticoEspanha
-
AHS Cancer Control AlbertaAlberta Cancer FoundationDesconhecido
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecrutamentoMesotelioma Pleural Bifásico | Mesotelioma Sarcomatóide PleuralEstados Unidos
-
Hospices Civils de LyonDesconhecido
-
Institut Claudius RegaudConcluído
-
Akamis BioBristol-Myers SquibbRecrutamentoCâncer metastático | Tumor EpitelialEstados Unidos, Reino Unido
-
Chang Gung Memorial HospitalDesconhecido
-
Asan Medical CenterAinda não está recrutando
-
Compugen LtdBristol-Myers SquibbAtivo, não recrutandoCâncer de mama | Cancro do ovário | Câncer de pulmão | Câncer de Mama Triplo Negativo | Câncer do endométrio | Câncer Avançado | Câncer colorretal | Neoplasia ovariana | Neoplasia Maligna | Neoplasia pulmonarEstados Unidos
-
Taipei Medical University WanFang HospitalConcluído